Alamar Biosciences

Sr. Director, Clinical Business Development

United States

Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Diagnostics, Healthcare, PharmaceuticalsIndustries

Requirements

Candidates must possess an advanced degree (PhD, MD, or MBA) in life sciences or a related field, with over 10 years of experience in clinical business development, ideally within the proteomics, diagnostics, or biotech sectors. A customer-centric approach, a proven history of closing strategic deals and managing complex partnerships, and a deep understanding of clinical trial design, biomarker validation, and regulatory frameworks are essential. Excellent communication, negotiation, and leadership skills are also required, along with innovative thinking and the ability to identify new growth opportunities.

Responsibilities

The Sr. Director, Clinical Business Development will lead strategic partnerships and commercial initiatives for Alamar's proteomics platform, focusing on clinical applications. This includes identifying, negotiating, and managing clinical collaborations and licensing opportunities, as well as developing and executing strategies for market expansion in clinical diagnostics and translational research. The role involves collaborating with R&D, regulatory, and commercial teams, engaging with key opinion leaders and decision-makers, providing input on clinical validation and regulatory pathways, and driving revenue growth through partnerships and co-development deals.

Skills

Proteomics
Early Cancer Detection
Biomarker Discovery
Clinical Assay Development
Regulatory Landscape
Strategic Partnerships
Licensing
Market Expansion
Clinical Diagnostics
Translational Research
Product Development
Customer Engagement
Key Opinion Leader Engagement
Clinical Validation
FDA
CE-IVD
Revenue Growth
Co-development Deals
Biopharma
Biotech
Diagnostics Companies
Clinical Research Organizations

Alamar Biosciences

Develops technology for protein detection and measurement

About Alamar Biosciences

Alamar Biosciences focuses on the study of proteins, known as proteomics, to enhance disease detection and treatment. The company has created NULISA™, a technology that can detect and measure proteins in the human body with high sensitivity and a wide range. This allows researchers and clinicians to profile clinically relevant protein biomarkers, which are essential for developing new diagnostic tests and treatments for various diseases. Alamar's ARGO™ system complements NULISA™ by providing a fully automated, high-throughput platform for precision proteomics. Unlike competitors, Alamar's technology simplifies the process, reducing the need for extensive technical expertise, making it more accessible to clients. The goal of Alamar Biosciences is to improve our understanding of proteins in health and disease, ultimately leading to better early detection and treatment options.

Hayward, CaliforniaHeadquarters
2018Year Founded
$225.7MTotal Funding
GRANTCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

401(k) Company Match
401(k) Retirement Plan
Performance Bonus
Company Equity

Risks

Increased competition from Olink and SomaLogic may impact Alamar's market share.
Scaling production in Europe and APAC could strain resources and affect quality.
Regulatory hurdles in new regions may delay product launches and affect revenue.

Differentiation

Alamar's NULISA™ technology offers unprecedented sensitivity in protein detection.
The ARGO™ system automates high-throughput proteomics, reducing the need for technical expertise.
Alamar's focus on early disease detection sets it apart in the biotechnology field.

Upsides

ISO 13485:2016 certification boosts Alamar's credibility in the medical device industry.
European expansion with Milan headquarters enhances market reach and client service.
$10M investment accelerates Alzheimer's diagnostics development, strengthening Alamar's market position.

Land your dream remote job 3x faster with AI